Corvus Pharmaceuticals (CRVS) Earnings Analysis

Corvus Pharmaceuticals (CRVS) next reports earnings on 2026-08-06, consensus EPS -0.17 USD. Last quarter (2026-05-07) it missed with EPS -0.15 USD vs -0.14 USD est (-7.1%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -25.44.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CRVS next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.17 USD
Revenue estimaten/a

CRVS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.15 USD-0.14 USD-7.1%Miss
2026-03-12-0.15 USD-0.14 USD-7.1%Miss
2025-08-07-0.1 USD-0.13 USD+23.1%Beat
2025-05-08-0.13 USD-0.13 USD0%Beat

Beat rate: 2/4 (50%) over reported quarters with consensus data.

CRVS valuation and analyst view

Trailing P/E-25.44
Trailing EPS-0.49077 USD
Price / book5.23
Dividend yield0.00%
Market cap1.17B
Analyst consensusBuy (12 buy / 1 hold / 0 sell)
Avg price target27.56 USD

Related research pages

Frequently asked questions

When is Corvus Pharmaceuticals (CRVS)'s next earnings date?

Corvus Pharmaceuticals is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.17 USD.

Did CRVS beat earnings last quarter?

In its 2026-05-07 report, CRVS posted EPS of -0.15 USD versus a -0.14 USD estimate — a miss of 7.1%.

What is CRVS's earnings track record?

Over the last 4 reported quarters with consensus data, CRVS beat estimates 2 times (50%).

What is CRVS's current P/E ratio and EPS?

CRVS trades at a trailing P/E of -25.44 on trailing EPS of -0.4907733978950879 USD.

What do analysts rate CRVS?

Analyst consensus is "Buy" across 13 ratings (0 strong buy, 12 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 27.56 USD.